

VERTEX PHARMACEUTICALS INC / MA

Form 8-K

May 20, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 20, 2005**

**VERTEX PHARMACEUTICALS INCORPORATED**

(Exact name of registrant as specified in its charter)

**MASSACHUSETTS**  
(State or other jurisdiction of  
incorporation)

**000-19319**  
(Commission File Number)

**04-3039129**  
(IRS Employer Identification  
No.)

**130 Waverly Street**  
**Cambridge, Massachusetts 02139**

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

(Address of principal executive offices) (Zip Code)

**(617) 444-6100**

Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On May 10, 2005, Vertex Pharmaceuticals Incorporated (the Company) issued a press release that announced interim results indicating that the Company's investigational oral hepatitis C virus (HCV) protease inhibitor, VX-950, was well-tolerated and demonstrated potent antiviral activity in a Phase Ib clinical trial. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On May 17, 2005, the Company issued a press release that described the results of the Phase Ib clinical trial in further detail. A copy of that press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(c) Exhibits**

<b>Exhibit</b>	<b>Description of Document</b>
99.1	Press Release of Vertex Pharmaceuticals Incorporated, dated May 10, 2005, titled Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study .
99.2	Press Release of Vertex Pharmaceuticals Incorporated, dated May 17, 2005, titled Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study .

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VERTEX PHARMACEUTICALS INCORPORATED**  
(Registrant)

Date: May 20, 2005

/s/ Kenneth S. Boger

**SIGNATURES**

Kenneth S. Boger  
Senior Vice President and General Counsel